Trial · NCT04128683

Dopamine Receptor Contributions to Prediction Error and Reversal Learning in Anorexia Nervosa

NCT04128683, Early phase 1, Completed, University of California, San Diego; results first posted 2025-04-11

3 sourcestrials-2026-11-12-0.4.0

Cite this record

ConductScience Library. Dopamine Receptor Contributions to Prediction Error and Reversal Learning in Anorexia Nervosa. Trials, record NCT04128683. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04128683

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Dopamine Receptor Contributions to Prediction Error and Reversal Learning in Anorexia Nervosa
NCT number: NCT04128683
Status: Completed
Phases: Early phase 1
Enrollment: 31 participants, actual
Lead sponsor: University of California, San Diego
Conditions: Anorexia Nervosa
Interventions: amisulpride, bromocriptine, Placebo
First posted: 2019-10-16
Last updated: 2025-04-11
Results first posted: 2025-04-11

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Measurement of Brain Activation (Measured in Percent Signal Change) During a Prediction Error Taste Reward Task Using Functional Magnetic Resonance Imaging (fMRI).	The outcome measure was assessed during the taste MRI task on each of the 3 intervention scan days over the course of 9 to 12 days	This task measures responsiveness to unexpected stimulus in the dopamine related brain circuitry. Study participants in both the healthy control group and anorexia nervosa group completed 3 fMRI scans. Prior to each scan subjects were administered one of three study medications (amisulpride, bromocriptine, or placebo). During the fMRI scan, subjects completed a taste reward prediction error task where they viewed visual stimuli and then received one of three conditions: sweet taste, neutral taste, or no solution. 20 percent of stimulus receipt was unexpected, that is there is a mismatch between expectation and outcome. Using a region of interest (ROI)-based approach, brain activation percent signal change values were extracted from the brain images for each subject and compared across groups and medication scans. A repeated measures ANOVA was used to calculate the mean brain activation for each group and each medication scan.
Primary	Measurement of Brain Activation (Measured in Percent Signal Change) During Taste Stimulus Expectation Using Functional Magnetic Resonance Imaging (fMRI).	The outcome measure was assessed during the taste MRI task on each of the 3 intervention scan days over the course of 9 to 12 days	Study participants in both the healthy control group and anorexia nervosa group completed 3 fMRI scans. Prior to each scan subjects were administered one of three study medications (amisulpride, bromocriptine, or placebo). During the fMRI scan, subjects completed a taste reward prediction error task where they viewed visual stimuli and then received one of three conditions: sweet taste, neutral taste, or no solution. Using a region of interest (ROI)-based approach, brain activation percent signal change values were extracted from the brain images for each subject and compared across groups and medication scans. Here only stimulus expectation data were analyzed. A repeated measures ANOVA was used to calculate the mean brain activation for each group and each medication scan.

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Measurement of Brain Activation (Measured in Percent Signal Change) During a Prediction Error Taste Reward Task Using Functional Magnetic Resonance Imaging (fMRI).	The outcome measure was assessed during the taste MRI task on each of the 3 intervention scan days over the course of 9 to 12 days	brain imaging data was pre-processed and brain response was analyzed across groups (healthy control group versus anorexia nervosa group) and within group for each medication. One participant in the anorexia nervosa group had to be excluded from the analysis results due to excessive movement throughout the MRI scan.	Percent Signal Change	MEAN
PRIMARY	Measurement of Brain Activation (Measured in Percent Signal Change) During Taste Stimulus Expectation Using Functional Magnetic Resonance Imaging (fMRI).	The outcome measure was assessed during the taste MRI task on each of the 3 intervention scan days over the course of 9 to 12 days	brain imaging data was pre-processed and brain response was analyzed across groups (healthy control group versus anorexia nervosa group) and within group for each medication	Percent Signal Change	MEAN

Source ClinicalTrials.gov

Results by group72

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Measurement of Brain Activation (Measured in Percent Signal Change) During a Prediction Error Taste Reward Task Using Functional Magnetic Resonance Imaging (fMRI).	Healthy Controls Placebo Scan	Left Ventral Insula Brain Activation	5.847	Standard Error 1.349	Percent Signal Change
Measurement of Brain Activation (Measured in Percent Signal Change) During a Prediction Error Taste Reward Task Using Functional Magnetic Resonance Imaging (fMRI).	Anorexia Nervosa Placebo Scan	Left Ventral Insula Brain Activation	5.083	Standard Error 1.596	Percent Signal Change
Measurement of Brain Activation (Measured in Percent Signal Change) During a Prediction Error Taste Reward Task Using Functional Magnetic Resonance Imaging (fMRI).	Healthy Controls Amisulpride Medication Scan	Left Ventral Insula Brain Activation	0.991	Standard Error 0.938	Percent Signal Change
Measurement of Brain Activation (Measured in Percent Signal Change) During a Prediction Error Taste Reward Task Using Functional Magnetic Resonance Imaging (fMRI).	Anorexia Nervosa Amisulpride Medication Scan	Left Ventral Insula Brain Activation	-1.047	Standard Error 1.109	Percent Signal Change
Measurement of Brain Activation (Measured in Percent Signal Change) During a Prediction Error Taste Reward Task Using Functional Magnetic Resonance Imaging (fMRI).	Healthy Controls Bromocriptine Medication Scan	Left Ventral Insula Brain Activation	1.116	Standard Error 1.225	Percent Signal Change
Measurement of Brain Activation (Measured in Percent Signal Change) During a Prediction Error Taste Reward Task Using Functional Magnetic Resonance Imaging (fMRI).	Anorexia Nervosa Bromocriptine Medication Scan	Left Ventral Insula Brain Activation	-0.148	Standard Error 1.450	Percent Signal Change
Measurement of Brain Activation (Measured in Percent Signal Change) During a Prediction Error Taste Reward Task Using Functional Magnetic Resonance Imaging (fMRI).	Healthy Controls Placebo Scan	Right Ventral Insula Brain Activation	4.095	Standard Error 0.669	Percent Signal Change
Measurement of Brain Activation (Measured in Percent Signal Change) During a Prediction Error Taste Reward Task Using Functional Magnetic Resonance Imaging (fMRI).	Anorexia Nervosa Placebo Scan	Right Ventral Insula Brain Activation	4.860	Standard Error 0.791	Percent Signal Change
Measurement of Brain Activation (Measured in Percent Signal Change) During a Prediction Error Taste Reward Task Using Functional Magnetic Resonance Imaging (fMRI).	Healthy Controls Amisulpride Medication Scan	Right Ventral Insula Brain Activation	0.883	Standard Error 0.716	Percent Signal Change
Measurement of Brain Activation (Measured in Percent Signal Change) During a Prediction Error Taste Reward Task Using Functional Magnetic Resonance Imaging (fMRI).	Anorexia Nervosa Amisulpride Medication Scan	Right Ventral Insula Brain Activation	-0.137	Standard Error 0.847	Percent Signal Change

1 to 10 of 72Source ClinicalTrials.gov

See all 72 results by group

Participant flow48

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
1st Intervention (1 Day)	STARTED	Healthy Controls	7
1st Intervention (1 Day)	STARTED	Anorexia Nervosa	6
1st Intervention (1 Day)	1st Intervention = Amysulpride	Healthy Controls	3
1st Intervention (1 Day)	1st Intervention = Amysulpride	Anorexia Nervosa	2
1st Intervention (1 Day)	1st Intervention = Bromocriptine	Healthy Controls	1
1st Intervention (1 Day)	1st Intervention = Bromocriptine	Anorexia Nervosa	2
1st Intervention (1 Day)	1st Intervention = Placebo	Healthy Controls	3
1st Intervention (1 Day)	1st Intervention = Placebo	Anorexia Nervosa	2
1st Intervention (1 Day)	COMPLETED	Healthy Controls	7
1st Intervention (1 Day)	COMPLETED	Anorexia Nervosa	6

1 to 10 of 48Source ClinicalTrials.gov

See all 48 participant flow

Adverse events12

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Fatigue	General disorders	Healthy Control Group Placebo Scan	0	7	0
other	Fatigue	General disorders	Anorexia Nervosa Group Placebo Scan	0	6	0
other	Fatigue	General disorders	Healthy Control Group Amisulpride Scan	0	7	0
other	Fatigue	General disorders	Anorexia Nervosa Group Amisulpride Scan	0	6	0
other	Fatigue	General disorders	Healthy Control Group Bromocriptine Scan	2	7	2
other	Fatigue	General disorders	Anorexia Nervosa Group Bromocriptine Scan	0	6	0
other	Dizziness	General disorders	Healthy Control Group Placebo Scan	0	7	0
other	Dizziness	General disorders	Anorexia Nervosa Group Placebo Scan	0	6	0
other	Dizziness	General disorders	Healthy Control Group Amisulpride Scan	0	7	0
other	Dizziness	General disorders	Anorexia Nervosa Group Amisulpride Scan	0	6	0

1 to 10 of 12Source ClinicalTrials.gov

See all 12 adverse events

Adverse event totals18

The totals the trial posted for each group.

Total	Group	At risk
Total, all-cause mortality	Healthy Control Group Placebo Scan	7
Total, all-cause mortality	Anorexia Nervosa Group Placebo Scan	6
Total, all-cause mortality	Healthy Control Group Amisulpride Scan	7
Total, all-cause mortality	Anorexia Nervosa Group Amisulpride Scan	6
Total, all-cause mortality	Healthy Control Group Bromocriptine Scan	7
Total, all-cause mortality	Anorexia Nervosa Group Bromocriptine Scan	6
Total, other adverse events	Healthy Control Group Placebo Scan	7
Total, other adverse events	Anorexia Nervosa Group Placebo Scan	6
Total, other adverse events	Healthy Control Group Amisulpride Scan	7
Total, other adverse events	Anorexia Nervosa Group Amisulpride Scan	6

1 to 10 of 18Source ClinicalTrials.gov

See all 18 adverse event totals

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
R21MH120475	Toward understanding dopamine receptor contributions to prediction error and reversal learning in anorexia nervosa	FRANK, GUIDO KW	UNIVERSITY OF CALIFORNIA, SAN DIEGO	NATIONAL INSTITUTE OF MENTAL HEALTH	2019 to 2020

Source NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Source

Release: trials-2026-11-12-0.4.0
Release manifest SHA-256: 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
Registry capture: 2026-11-12
Results copy, AACT: 2026-03-23
NIH clinical studies file: 2026-11-13

Source ClinicalTrials.gov

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNone stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT04128683

GET https://conductscience.org/api/trials/v1/NCT04128683/results?page=2

API reference For AI assistants